|
Commitments and Contingencies (Details Textual 1) (USD $)
|
0 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 9 Months Ended | 0 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 9 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 01, 2012
Rental Agreement [Member]
|
Sep. 30, 2013
Rental Agreement [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
|
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
|
Feb. 28, 2002
Memorial Sloan Kettering Cancer Center [Member]
License agreement [Member]
|
Sep. 30, 2013
Memorial Sloan Kettering Cancer Center [Member]
License agreement [Member]
|
Mar. 27, 2012
Memorial Sloan Kettering Cancer Center [Member]
Clinical Trial Agreement [Member]
|
Sep. 30, 2013
Oak Ridge National Laboratory [Member]
|
Aug. 06, 2012
Aptiv Solutions [Member]
|
Sep. 30, 2013
Aptiv Solutions [Member]
|
Dec. 31, 2012
Aptiv Solutions [Member]
|
Dec. 31, 2007
Aptiv Solutions [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Sep. 30, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Maximum [Member]
|
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Minimum [Member]
|
Jul. 19, 2012
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
|
Aug. 28, 2012
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
Installment
|
Sep. 26, 2012
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
|
Nov. 21, 2012
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
|
Mar. 31, 2013
Former CEO [Member]
Separation and Settlement Agreement [Member]
|
Sep. 30, 2013
Former CEO [Member]
Separation and Settlement Agreement [Member]
|
Feb. 28, 2013
Former CEO [Member]
Separation and Settlement Agreement [Member]
|
|
| Commitments and Contingencies (Textual) | |||||||||||||||||||||||||
| License fee payment | $ 3,000,000 | ||||||||||||||||||||||||
| Milestones payments | 7,750,000 | 1,500,000 | 750,000 | ||||||||||||||||||||||
| Net sales in milestones payment | 10,000,000 | 1,000,000 | |||||||||||||||||||||||
| Description of royalty payment | We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. | We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. | Royalty payments of 2% of net sales will be due to FHCRC. | ||||||||||||||||||||||
| Royalty of Net Sales Percentage | 12.00% | ||||||||||||||||||||||||
| First commercial sale period | 12 years 6 months | ||||||||||||||||||||||||
| Technology access fee | 50,000 | ||||||||||||||||||||||||
| Annual maintenance fee | 50,000 | ||||||||||||||||||||||||
| Annual research funding | 50,000 | ||||||||||||||||||||||||
| Purchase of radioactive material used for research and development | 233,100 | ||||||||||||||||||||||||
| Project estimated cost for clinical trials of drug Ac-225-HuM195 | 1,859,333 | ||||||||||||||||||||||||
| Down payment of project estimated cost percentage | 12.50% | ||||||||||||||||||||||||
| Down payment for project | 1,997,732 | 239,000 | 239,000 | ||||||||||||||||||||||
| Clinical trial cost for approval of food and drug administration | 23,500,000 | 13,200,000 | |||||||||||||||||||||||
| Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) | 150,000 | ||||||||||||||||||||||||
| Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) | 250,000 | ||||||||||||||||||||||||
| Number of Patients | 24 | ||||||||||||||||||||||||
| Amount paid to each patient after Completing clinical trial | 31,185 | 31,366 | 481,204 | 38,501 | 31,771 | ||||||||||||||||||||
| Start-up fee for clinical trial | 79,623 | 19,749 | 33,946 | 22,847 | 16,000 | ||||||||||||||||||||
| Start-up due cost paid date | Jul. 10, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | ||||||||||||||||||||||
| Non-refundable institutional fee | 14,500 | ||||||||||||||||||||||||
| Annual pharmacy fee | 2,025 | ||||||||||||||||||||||||
| Amendment processing fee | 500 | ||||||||||||||||||||||||
| Consideration pursuant to agreement | The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012. | ||||||||||||||||||||||||
| Performance bonus payable under agreement for service | 60,000 | ||||||||||||||||||||||||
| Notice period for termination of agreement | This agreement terminates on Decemeber 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. | ||||||||||||||||||||||||
| Rent agreement termination date | Dec. 31, 2013 | ||||||||||||||||||||||||
| Rental agreement renewal description | The agreement automatically renews on a month-to-month basis and requires a two month notice of termination. | ||||||||||||||||||||||||
| Payment of aggregate amount in installments | 125,000 | ||||||||||||||||||||||||
| Outstanding payment of final installment for services by company | 125,000 | ||||||||||||||||||||||||
| Payment of performance bonus for services by company | $ 60,000 | ||||||||||||||||||||||||